



MESSAGE
FROM CEO

Dear Esteemed Patron,

On behalf of the OncoStem family, I extend warm wishes for a joyous Makar Sankranti and a prosperous 2024.

We are thrilled to share significant milestones achieved in the past year, marking **OncoStem's 12th anniversary**. Notably, we celebrated the milestone with the publication of our **first-ever prospective randomized completed trial** and the establishment of a **strategic partnership on CanAssist Breast with Zydus Lifesciences**.

Our collaboration with Zydus, a recognized player in Oncology, aligns seamlessly with our shared commitment to advancing healthcare beyond conventional boundaries. Engaging in advisory meetings with many of you has been a valuable learning experience, and we have presented CAB data in various conferences, aiming to raise awareness about CAB.

In the **realm of research**, we completed analysis and publication showcasing **CAB can predict 10-year distant recurrences** in collaborating with a **team in The Netherlands**. Additionally, we also showcased the utility of **CAB in multi-focal/centric tumors and in core needle biopsies**. These endeavours are geared towards enhancing confidence in CanAssist Breast, both for us and for you.

We have received heart-warming **testimonials from patients** who, having completed **five years without chemotherapy, remain disease-free**. Their resilience continues to inspire and drive our commitment to excellence.

We are pleased to announce the successful signing of contracts to enter **CAB in Saudi Arabia and Iran**. This aligns with our strategic roadmap for the continued growth of CanAssist Breast in the West Asia region.

I am hopeful for the opportunity to meet many of you in person throughout the year. I extend a **heartfelt thanks to each of you for your unwavering belief in us** and for contributing to making a **meaningful difference in the lives of breast cancer patients**.

Wishing you continued success and good health.

Regards
Manjiri

OncoStem and Zydus officially launched a strategic partnership on CanAssist Breast.



OncoStem Upgrades its IHC staining facility!



- Focused on expanding our testing capabilities to match the increasing volumes and improve TAT.
- OncoStem adds another fully automated Immunohistochemistry staining system, the Ventana Benchmark Ultra.
- With 30 independent slide drawers and single-piece workflow, Ventana Benchmark Ultra improves quality, workflow, and operational flexibility.
- Continuous and random slide processing improves testing efficiency.

How has CanAssist Breast Data strengthened in the year 2023?




TEAM TRIAL

CAB validated to predict 10 year recurrence

For the first time, we showcased that CAB can predict

- i) 10 year distant recurrences and
- ii) CT benefit in high-risk only via a prospective randomized European completed trial called TEAM.



CAB & Ki67 Comparison:

Which is more sensitive?


CAB found

- i) ~20% patients as 'high risk' who had Ki67 <5%
- ii) actionable prognostic information in intermediate Ki67 group
- iii) Over all, 30% more patients as "low-risk" with identical DRFI.



Usefulness of CAB in Multifocal/Multicentric tumors

What are Multifocal/Multicentric tumors:
When more than one distinct tumor is present within the same/different quadrants of the breast, respectively.



First CAB is performed on tumor with highest clinical risk i.e. higher Tumor Size/Grade/①

Low Risk for Recurrence
Perform CAB on the next biggest tumor / ② to decide the treatment
*Additional testing is chargeable

High Risk for Recurrence
Additional CAB testing is not needed

On testing the second tumor Recurrence Risk category changed from **low to high** risk in 4 cases(11%). **All second tumors tested were smaller in size compared to first.**



37 Multifocal / Multicentric cases analyzed

CAB is beneficial in multifocal/multicentric tumors to plan optimum therapy

CNB vs Excision comparison

97.5% concordance on low risk between CAB performed on Core Needle Biopsy (CNB) and Excision Samples. CAB risk category based on CNB can help you to plan optimum neo-adjuvant therapy.


CAB performed on Core-needle biopsy Vs excision sample

CanAssist Breast was performed on 103 paired Core Needle biopsy (CNB) and Excision samples.

T1 & T2 with a median tumor size of 2.5 Cms.

Concordance on LR between CNB and excision sample: 97.5%→implying minimal effect on treatment decision, if CNB is used as primary sample for CanAssist Breast.

Overall percentage agreement between CAB Risk score for CNB Vs Excision is 92.2% and Pearson correlation of $r = 0.8351$ ($P < 0.0001$).



T1	30
T2	73
N0	75
N1	18
T1N0	26
T2N0	58
T1N1	4
T2N1	14

Correlation	
Variable Y	Core_Risk_Score
Variable X	Excision_Risk_Score
Sample size	103
Correlation coefficient r	0.8351
Significance level	$P < 0.0001$
95% Confidence interval for r	0.7853 to 0.8855

CAB enters Asian Geriatric Oncology Society guidelines

CanAssist Breast is included in Asian Geriatric Oncology Society' Guidelines.

Parikh et al. *BMC Cancer* (2023) 23:714
https://doi.org/10.1186/s12885-023-11121-9

RESEARCH Open Access

Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method

Purvish Parikh¹, Govind Babu², Randeep Singh³, Vamshi Krishna⁴, Amit Bhatt⁵, Indu Bansal³, Senthil Rajappa⁶, Tarini Prasad Sahoo⁷, Shyam Aggarwal⁸, Ajay Bapna⁹, Ghanshyam Biswas¹⁰, SP Somashekhar¹¹, Jyoti Bajpai², Vashishtha Maniar¹³, Sharad Desai¹⁴, T Raja¹⁵ and Goura Kishor Rath¹⁶

Table 2 Practical Consensus Guidelines for optimizing the benefit of chemotherapy in the management of HR positive HER2/neu negative early breast cancer

Consensus Guidelines statements

CanAssist Breast and Oncotype DX are the recommended multi-marker prognostic tests that have substantial documented evidence.

The only currently available predictive test for HR positive HER/neu2 negative EBC that has been validated in Indian patients is CanAssist Breast.

Prospective usage of CAB in real world

A single center study highlights how CanAssist Breast is helping to plan treatment in India in a prospective manner.

OPEN ACCESS Original Article

Risk Stratification of Early Breast Cancer (HR +/-HER2-) by CanAssist Breast and Its Correlation with Other Online Prognostic Tools: Experience from a Single Center

Ajay Bapna¹ Sanjeev Patni² Nidhi Patni³ Anil Kumar Gupta² Aseem Kumar Samar¹ Naresh Ledwani² Tarachand Gupta¹ Pawan Agarwal¹

¹ Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC), Jaipur, Rajasthan, India
² Department of Surgical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC), Jaipur, Rajasthan, India
³ Department to Radiation Oncology, Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC), Jaipur, Rajasthan, India

Address for correspondence: Ajay Bapna, MD, Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital and Research Center, Jaipur 302017, Rajasthan, India (e-mail: ajaybapna74@gmail.com).

Inf J Med Paediatr Oncol

Advisories and Conferences where CAB was discussed

December 2022

CanAssist Breast advisory meeting in Delhi.



CanAssist Breast advisory meeting in Kolkata.




January 2023

Presented CAB test at The West Bengal Chapter of the Association of Surgeons of India.



February 2023

Dr. B. A. Savitha showcased the CAB test at 28th AIPNA - ICP International CME in pathology 2023.




March 2023

Dr. S. P. Somashekar shared insights about the CAB test at ABSI Midcon 2023 which was held in Patna.



April 2023

Dr. Manjiri Bakre presented data on the CAB test at an advisory meeting in Ahmedabad.



June 2023

Dr. Manjiri Bakre gave a talk on the CAB test at Acharya Harihar Post Graduate Institute of Cancer, Bhubaneswar.



July 2023

Advisory & conference talks given by Dr. Manjiri Bakre at ABSICON, (Association of Breast Surgeons of India) Ahmedabad.



October 2023

Talk given by Dr. D. G. Vijay at Association of Surgeons of India (ASICON).



CME talk given by Dr. D.G.Vijay

Dr. D. G. Vijay explained data on CanAssist Breast in a CME at Udaipur, Rajasthan.



November 2023

Presented an Advisory about the CAB test at ICC, Mumbai



November 2023

Dr. Mandeep Singh shared groundbreaking insights about the CanAssist Breast Test at OFCON Conference, New Delhi.



December 2023

Talk given by Dr. Manjiri Bakre on 'Does every breast cancer patient need chemotherapy? And Role of "Made in India" innovative tests in decision making' to talented audience of Pathologists and Microbiologists at GAPM 2023 in Vadodra.



CanAssist Breast test gets

Dr. Pramod Kumar Julka, Vice Chairman of Max Healthcare, shares his positive views about the benefits of CanAssist Breast and how it has helped his patients.



Patient Testimonials

“

I was diagnosed with Breast Cancer, the doctor suggested that I go with the CAB test. As a clinician myself, I was totally happy with my experience with CanAssist Breast Test. CanAssist's accurate and reliable results gave me the confidence to make informed decisions about my health. I highly recommend CanAssist to anyone seeking a trustworthy and effective breast test. Thank you, CanAssist for empowering patients like me!

— A Clinician who was diagnosed with Breast Cancer

”

“

I am from the rural part of Karnataka, access to advanced medical services can be challenging. But thanks to CanAssist Team, I was able to take the test and receive the amazing news that I could skip chemotherapy. The convenience of getting this test done was truly impressive. I am so grateful for the service provided by CanAssist Team. I highly recommend it to anyone, especially those in rural areas, who are seeking reliable and accessible medical solutions.

— Breast cancer survivor from Rural Part of Karnataka

”

Other Key Highlights

Panel discussion in Ministerial G20 with Dutch Delegation

OncoStem was part of a panel discussion on “understanding start-up ecosystems in India and The Netherlands” as part of the Dutch economic delegation on med-tech in the backdrop of the Ministerial G20, in the month of September.



A talk given at ICGA conference at Pune

OncoStem participated in an invited talk in “Indian Cancer Genome Atlas” (ICGA) conference in Pune which showcases latest advances and challenges in cancer genomics research and precision medicine in India and beyond.

